Our previous study had reported that
cholesterol-grafted
poly(amidoamine) (rPAA-Chol
polymer) was able to self-assemble into cationic nanoparticles and act as a potential carrier for
siRNA transfection. In this study, the core-shell type
lipid/rPAA-Chol hybrid nanoparticles (PEG-LP/
siRNA NPs and T7-LP/
siRNA NPs) were developed for improving in vivo
siRNA delivery by modifying the surface of rPAA-Chol/
siRNA nanoplex core with a
lipid shell, followed by post-insertion of
polyethylene glycol phospholipid (
DSPE-PEG) and/or
peptide (HAIYPRH, named as T7) modified DSPE-PEG-T7. The integrative hybrid nanostructures of LP/
siRNA NPs were evidenced by dynamic light scattering (DLS), confocal
laser scanning microscope (CLSM), cryo-transmission electron microscope (Cryo-TEM) and surface plasmon resonance (SPR) assay. It was demonstrated that the
T7 peptide modified LP/
siRNA NPs (T7-LP/
siRNA NPs) exhibited uniform and spherical structures with particle size of 99.39 ± 0.65 nm and surface potential of 42.53 ± 1.03 mV, and showed high cellular uptake efficiency and rapid endosomal/lysosomal escape ability in MCF-7 cells. Importantly, in vitro gene silencing experiment demonstrated that both of pegylated and targeted LP/siEGFR NPs exhibited significantly stronger downregulation of EGFR
protein expression level in MCF-7 cells, compared to that of the physical mixture of
siRNA lipoplexes and rPAA-Chol/
siRNA nanoplexes. In vivo
tumor therapy on nude mice bearing MCF-7
tumors further confirmed that the targeted T7-LP/siEGFR NPs exhibited the greatest inhibition on
tumor growth via
transferrin receptor-mediated targeting delivery, without any activation of immune responses and significant
body weight loss following systemic administration. These findings indicated that the core-shell type T7-LP/
siRNA nanoparticles would be promising
siRNA delivery systems for in vivo
tumor-targeted
therapy.